Seeking Alpha

The Medicines Co. (MDCO +2%) may benefit from new antibiotics regulation, says Leerink Swann....

The Medicines Co. (MDCO +2%) may benefit from new antibiotics regulation, says Leerink Swann. Current bills in the House and Senate extend the market exclusivity period for new antimicrobial drugs by five years, and grant six additional months of data exclusivity for antibiotics with companion diagnostics. Leerink thinks MDCO's Oritavancin may qualify for an additional five years of "antibiotic exclusivity," which it feels could double the drug's value.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector